language_icon
EN
HI

Indegene Share price

INDGN

498.7

11.45 (2.35%)
NSE
BSE
Last updated on 22 Apr, 2026 | 15:45 IST
Today's High

500.40

Today's Low

482.10

52 Week Low

414.00

52 Week High

632.90

Zero AMC

Free Demat with Zero AMC*

Open a Free Demat Account
+ Free 1st Year AMC

Indegene Chart

Indegene Share Key Metrics

Volume
2.07 L
Market Cap
12009.09 CR
LTQ@LTP
50@498.70
ATP
491.59
Var Margin
16.16 %
Circuit Range
389.8-584.7
Delivery %
55.09 %
Value
10.16 CR
ASM/GSM
No
Market Lot
1

Summary

Indegene share price stands at ₹498.7 at 22 Apr, 2026 | 15:45. The stock Indegene intraday movement has stayed between ₹482.10 and ₹500.40, while on a 52-week basis it has fluctuated from ₹414.00 to ₹632.90.
In terms of trading activity, Indegene has recorded a volume of 206759 shares. The Indegene has a market cap of ₹240807964. The stock’s Average Traded Price (ATP) stands at ₹49159, while the Last Traded Quantity at Last Traded Price (LTQ@LTP) is 50, 49870.
The Indegene operates within a circuit range of ₹389.8-584.7 – ₹389.8-584.7, with a Value of ₹10.16 CR. The Delivery Percentage for the day is 55.09%. Additionally, Indegene currently falls under the No framework, and trades with a market lot size of 1.

Indegene Fundamentals

View More
P/E Ratio

26.77

P/B Ratio

3.96

Div. Yield

0.41

Sector P/E

23.84

Sector P/B

2.88

Sec. Div. Yield

1.13

Indegene Resistance and Support

Pivot 485.73

Resistance

First Resistance

491.41

Second Resistance

495.58

Third Resistance

501.26

Support

First Support

481.56

Second Support

475.88

Third Support

471.71

Indegene Shareholding Pattern

View More
  • 2024-25
  • 2025-26
  • 2026-27
Total Promoters
Segment
Percent

Total Promoters

0%

Mutual Fund

4.7%

Insurance

0.01%

Foreign Institutional Investors

10.27%

Domestic Institutional Investors

3.59%

Retail

81.44%

Others

-0.01%

Total Promoters
MAR '26
0%

Indegene Corporate Actions

DateAgenda
2026-01-29Quarterly Results & ESOP
2025-10-30Quarterly Results
2025-07-31Quarterly Results
2025-04-28Audited Results & Final Dividend
2025-01-30Quarterly Results & Others

Indegene News

Indegene Limited

Indegene Limited board to meet on April 29, 2026, to consider a final dividend and audited FY26 standalone and cons. financial results.
Apr 21 2026 18:04:00

Indegene Ltd - 544172 - Board Meeting Intimation for Consideration And Approval Of Audited Financial Results Of The Company And Recommendation Of Final Dividend For The Year Ended March 31, 2026.

Indegene Limited's board is scheduled to meet on April 29, 2026. The agenda includes approving Q4 and FY26 financial results and recommending a final dividend. The meeting will also consider both audited consolidated and standalone financial results.
Apr 21 2026 17:04:00

Indegene Limited

Indegene's UK subsidiary, Indegene Healthcare UK Ltd, acquired the trade and business assets of Trilogy Writing & Consulting Limited. This intra-group transaction, executed on April 1, 2026, involves the sale of assets as a going concern and is part of the normal course of business.
Apr 01 2026 18:04:00
Read More

About Indegene

NSE : 23693  
BSE : 544172  
ISIN : INE065X01017  

Our Company was incorporated as ‘Indegene Lifesystems Private Limited’ at Ahmedabad Gujarat as a private limited company under the Companies Act 1956 pursuant to a certificate of incorporation dated October 16 1998 issued by the Registrar of Companies Gujarat Dadra & Nagar Haveli at Ahmedabad. Thereafter the registered office of our Company was shifted from Gujarat to Karnataka in June 2003 and then from Karnataka to Maharashtra in May 2014. Further pursuant to a resolution passed by our Shareholders at the EGM held on February 29 2016 the name of our Company was changed to ‘Indegene Private Limited’ and a fresh certificate of incorporation was issued by the Registrar of Companies Maharashtra at Mumbai on May 26 2016. The name of our Company was changed to better reflect the nature of business undertaken by our Company. Thereafter the registered office of our Company was shifted from Maharashtra to Karnataka in February 2017. Subsequently our Company was converted from a private limited company to a public limited company pursuant to a special resolution passed by our Shareholders at the EGM held on November 7 2022 and the name of our Company was changed to ‘Indegene Limited’ and a fresh certificate of incorporation was issued to our Company by the RoC on November 17 2022.Major events and milestones:2005-Raised funding from Nadathur Holdings & Investments Private Limited-Expanded operations to the USA by incorporating a subsidiary named Indegene Inc.-Expanded operations to Southeast Asia by incorporating a subsidiary named Indegene Fareast Pte. Ltd. in Singapore2006-Acquisition of Medsn Inc.1 a company in the USA which is engaged in medical education and marketing business by one of our Material Subsidiaries Indegene Inc.2 through the merger of Medsn Merger Sub Inc. an erstwhile wholly owned subsidiary of Indegene Inc. with Medsn Inc.2007-Expanded our services to include European territory2008-Received BS ISO/IEC 27001:2005 certification for information security management system32009-Received ISO 9001:2000 certification for quality management system42012-Expanded operations to China by incorporating a subsidiary named Indegene Lifesystems Consulting (Shanghai) Co. Ltd.2017-Acquisition of the Encima Group Inc. a corporation which operates a digital service marketing automation and analytics services business supporting clients in healthcare life sciences and other industries by one of our Material Subsidiaries ILSL Holdings Inc.2020-Acquisition of DT Associates Research and Consulting Services Limited a consulting services company in UK supporting clients in healthcare life sciences and other industries by one of our Material Subsidiaries ILSL Holdings Inc.-Launched Indegene Digital Summit a symposium on digital transformation and customer experience in life sciences2021-Expanded operations to Japan by incorporating a subsidiary named Indegene Japan LLC-Raised equity funding from CA Dawn Investments and Brighton Park Capital-Received BS ISO/IEC 27701:2019 certification for privacy information management system52022-Acquisition of Medical Marketing Economics LLC by one of our Material Subsidiaries ILSL Holdings Inc. and subsequent merger of Medical Marketing Economics LLC with Indegene Inc.-Expanded global operations with new offices in Mexico2023-Acquisition of Cult Health a company engaged in the business of providing advertising services to parties in the healthcare sector by one of our Material Subsidiaries ILSL Holdings Inc.-Expanded our presence in Europe with the acquisition of Indegene Healthcare Germany GmbH (formerly Sotus 852 GmbH) by our subsidiary Indegene Ireland Limited-Launched Invisage an AI-enabled hybrid omnichannel sales and marketing platform2024-Acquisition of Trilogy Writing & Consulting GmbH a company engaged in providing high-end medical writing to customers that include market-leading pharmaceutical companies along with three of its wholly owned subsidiaries by one of our Subsidiaries Indegene Ireland Limited.-Ranked 167 in The Next 500 India’s Largest Emerging Companies by Fortune India

Read More

Indegene Management

NamePosition
Srishti Ramesh KaushikCompany Secretary & Compliance Officer
Manish GuptaChairman, Chief Executive Officer
View More

Indegene FAQs

The Buying Price of Indegene share is 498.7 For live prices and instant trading, you can log in to your Choice trading account or open a Free Demat account with Choice.

To buy Indegene stocks, log in to your Choice trading account. If you don’t have one, open a Choice Demat account. Then, add funds, search for Indegene, choose your preferred order type, and place the trade.

The Price-to-earnings (P/E) ratio of Indegene shares is 26.77. You can compare it with the sector average for relative valuation.

The Price to Book (P/B) ratio Indegene shares is 3.96. Useful to assess the stock's value relative to its book value.

To assess Indegene’s valuation compare Sector P/E, P/B which are 23.84 & 2.88 with sector averages, along with growth rates and financial metrics.

The Market Cap of Indegene is 12009.09 CR. It indicates the company's size category and trading liquidity.

The 52 week high and low prices of Indegene share price is 632.90 & 414.00. They indicate price extremes, trading ranges, volatility measures, potential support/resistance, and price momentum.

Indegene belongs to the Miscellaneous sector.

Invest with Zero-Cost Demat Account

Zero AMC for First Year
Free Research Calls
₹ 0 Trade & Call Fee
Zero-Cost